Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
- Associated Therapies
- -
Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 82
- Registration Number
- NCT06417229
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 18
- Registration Number
- NCT06264440
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules
- Conditions
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- TenNor Therapeutics (Suzhou) Limited
- Target Recruit Count
- 40
- Registration Number
- NCT06076681
- Locations
- 🇨🇳
The First Hospital of Jilin University, Chang chun, Jilin, China
Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants
- Conditions
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- TenNor Therapeutics (Suzhou) Limited
- Target Recruit Count
- 80
- Registration Number
- NCT06076694
- Locations
- 🇨🇳
The First Hospital of Jilin University, Chang chun, Jilin, China
A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 28
- Registration Number
- NCT06054464
- Locations
- 🇺🇸
Parexel International, Baltimore, Maryland, United States
HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 24
- Registration Number
- NCT05930119
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
A Study of Maribavir Pediatric Formulation in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 32
- Registration Number
- NCT05918822
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 42
- Registration Number
- NCT05899829
- Locations
- 🇨🇦
GSK Investigational Site, Quebec City, Quebec, Canada
Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-05-15
- Target Recruit Count
- 855
- Registration Number
- NCT05718609
- Locations
- 🇨🇳
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China
HMPL-523 Food Effect and Proton Pump Inhibitor Study
- Conditions
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 26
- Registration Number
- NCT05571787
- Locations
- 🇺🇸
PPD Austin, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.